RGNX News and Press, REGENXBIO Inc. From 11/29/23

REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial PR Newswire First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On...

2023-11-08 22:26:02 ET REGENXBIO Inc. (RGNX) Q3 2023 Earnings Conference Call November 08, 2023 04:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - Chief Executive Officer Steve Pakola - Chief Medical Officer Vit Vasista - Chi...

2023-11-08 16:14:44 ET More on Regenxbio Regenxbio: Biotech To Watch With 2 Possible Accelerated Approval Pathways Regenxbio: Promising Yet Risky Therapeutic Horizon Regenxbio Q3 2023 Earnings Preview Stifel starts Regenxbio at buy; cites broad platform, deep...

REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results PR Newswire Announces pipeline prioritization and corporate restructuring to focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value ge...

2023-11-08 08:04:15 ET Summary EYP-1901 shows potential in wet AMD, underpinned by EyePoint's financial stability and innovative Durasert technology. Despite a decrease in product sales, increased R&D spend and a stable cash position suggest a robust pipeline focus. The DA...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

2023-11-07 12:10:51 ET More on Regenxbio Regenxbio: Biotech To Watch With 2 Possible Accelerated Approval Pathways Regenxbio: Promising Yet Risky Therapeutic Horizon Regenxbio: RGX-314 Continues Advancing With Solid Financials Stifel starts Regenxbio at buy; ...

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery PR Newswire ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with...

REGENXBIO Inc. (RGNX) is expected to report $-1.37 for Q3 2023

2023-11-02 17:33:57 ET Summary Regenxbio Inc. is making progress in its pipeline, aiming to have five gene therapies in late-stage testing or approved by 2025. The company's lead candidate, ABBV-RGX-314, is being developed for the treatment of wet age-related macular degeneration;...